IL17A and rheumatoid arthritis: Cardiovascular mortality was lowered by targeted anti-inflammatory therapy in patients with psoriasis (interleukin (IL)-17/IL-23 axis) [42,43,44], systemic lupus erythematosus (IL-17A signaling) [45], and rheumatoid arthritis (IL-6, tumor necrosis factor (TNF)-α, and IL-17A cascades) [46,47], further reinforcing the integral role of inflammation in cardiovascular disease.